As of 10:08 on August 22, 2023, the Nasdaq Biotech ETF (513290)**113%, the latest price quoted at 107 yuan, the intraday turnover has reached 180540,000 yuan, temporarily ranking first in comparable ETFs, with a turnover rate of 107%。
In terms of scale, the scale of the Nasdaq Biotech ETF has increased by 2546 in the past two weeks380,000 yuan, a significant increase, and the new scale ranked first in comparison.
In the long run, there have been 9 net inflows of funds in the past 10 trading days, with a total of 2908310,000 yuan, with an average daily net inflow of 290830,000 yuan.
Eastern time on Monday, U.S. vaccine stocks rose, Novavax Pharmaceuticals rose 13%, and Moderna rose 9%.3%, Biontech rose 65%, and Pfizer, the largest market capitalization, rose nearly 1%.
CITIC** said that the global clinical stage of new drug research and development is still active, although the demand for early stage research and development is temporarily weak, but with the recovery of overseas investment and financing, it is also expected to return to the normal of rapid growth. The revenue of upstream life science service providers has been affected by the destocking cycle of downstream enterprises, but enterprises generally believe that there will be an inflection point of new demand in 23Q4.
Nasdaq Biotech ETF (513290), OTC Connect (Class A: 017894; Category C: 017895; CUAM NASDAQ Biotech ETF Initiator Connect (QDII) USD Spot Rate: 017951; CUAM NASDAQ Biotech ETF Initiation Connect (QDII) USD Notes: 017952).
Risk Warning: All the information presented by Lianyun on the interface is for reference only and does not constitute investment advice, and all investment operation information cannot be used as an investment basis. Investment is risky, and you need to be cautious when entering the market!